Dasatinib and bosutinib have dual inhibitory action against SRC and ABL kinase that address most of the BCR-ABL mutations associated with TKI resistance except V299, E255, and T315I.41,42 Ponatinib, a pan-BCR-ABL inhibitor, has a great efficacy against native and mutated BCR-ABL1 including the T315I variant.43 However, a dose-dependent increased risk of developing arterial occlusion, stroke, limb ischemia, and other vascular events has been found.44,45 Asciminib is an allosteric inhibitor, unlike other TKI inhibitors, that binds the myristoyl pocket of BCR-ABL. Here, ABL1 is linked to arterial occlusion.